chrisvoncsefalvay/vaers-outcomes huggingface dataset:
high temperature (104F); convulsion-type chills (could not stop shaking); Headache; sore muscles; nauseous; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (high temperature (104F)), CHILLS (convulsion-type chills (could not stop shaking)), HEADACHE (Headache), MYALGIA (sore muscles) and NAUSEA (nauseous) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced PYREXIA (high temperature (104F)), CHILLS (convulsion-type chills (could not stop shaking)), HEADACHE (Headache), MYALGIA (sore muscles) and NAUSEA (nauseous). On 14-Mar-2021, PYREXIA (high temperature (104F)), CHILLS (convulsion-type chills (could not stop shaking)), HEADACHE (Headache), MYALGIA (sore muscles) and NAUSEA (nauseous) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment information was provided.
Narrative: Shortness of breath.  Treatment: Diphenhydramine 50mg once, Methylprednisolone 125mg once, Albuterol/Ipratropium 4 Puff(s) once
Fatigued; headache; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 11Apr2021 at 14:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patients' medical history was reported as none. It was unknown if the patient was pregnant. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not receive any medication within two weeks of the COVID-19 vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 21Mar2021 at 11:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 11Apr2021, at 17:45 the patient experienced headache which came and went. On 12Apr2021, the day after vaccination the patient felt fatigued and the patient reported that the pain intensity had decreased. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as the result of adverse events. The clinical outcome of the events headache and fatigue were recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
I had cough, fatigue, muscle aches, congestion, fever. My daughter was at an outdoor camp and we had been notified that she had been exposed to COVID-19. We thought we had Summer colds but once we tested using the home COVID-19 test they showed up positive. We called and had a telehealth visit as we had been a week in to the whole exposure we were advised to take over the counter medication.
My head was burning. I been having headache that was continuing. I wind up going to the ER. They did a CT scan to make sure that I did not have any brain bleed. They though I might have shingles on my head. I also had an ER visit 2 days later. I had abdominal pain. They sent me to get a CT scan of my abdominal and found a hernia. They did blood work for blood work done on both visits, normal results.
Hives, swollen red itchy eyes, puffy face and eyes, rash on the shoulder.
Information has been received from a pharmacist referring to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions and medical history were not reported. On an unknown date the patient was vaccinated with GARDASIL 9 (lot # L037339 with expiration date 09-FEB-2018, strength, dose and route were unknown) that were improperly stored. No adverse effects reported. Additional information has been requested.
Patient received the vaccine at approximately 10:15am at the Vaccine POD, patient stated that her face felt warm, as she pulled down her mask to look the patient states she saw large, red whelps across her face and neck. The patient then proceeded to the Vaccine POD First Aid station at approximately 10:47am and shared her symptoms with the paramedic. Upon assessment, the pt had large, red, raised hives across her face, neck, chest and back. Patient denies any complaint of itching, difficulty breathing or swallowing. Patient given 12.5mg liquid diphenhydramine by mouth. Patient continued in First Aid area for approximately 15 minutes. Hives were noticed to begin to diminish, and patient stated she felt improved.
This spontaneous report was received from a registered nurse and refers to a 4-month-old patient of unknown gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On 21-DEC-2018, the patient was vaccinated with improperly stored dose of PEDVAXHIB lot # R014261, expiration date 25-MAR-2021 or lot # R005118, expiration date 28-NOV-2020 (dose and route of administration were not reported). Administered dose of vaccine experienced the temperature excursion of 31.1 Fahrenheit degrees (F) (below 32 F/0 Celsius degrees) (30 cycles) for 35 hours 30 minutes. There were no previous excursions reported. The digital data logger was involved to capture the temperature excursion. No adverse effects were reported. This is one of multiple reports received from the same reporter (it was reported that it was unknown which lot numbers of each specific vaccine were administered to which patient). Sender's Comments: US-009507513-1901USA000071.
Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Allergic: Rash Generalized-Mild, Additional Details: patient reported a rash on neck that appeared in one spot and seemed to be growing a little bit, and also some new redness on her chest
Shortly after immunization, patient started to develop a rash around the injection site as well as nausea.  Given Benadryl and transferred to the Emergency Department.
Patient reported to have no sensation last for 15 minutes  from her hip to feet after received the 2nd dose of  Moderna covid vaccine 14 hours.
Herpes Zoster ophthalmicus; right Bell's Palsy; facial paralysis; shingles; other zoster related injuries; varicella type rash; Information has been received regarding a case in litigation regarding a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant medication.  On or about 15-APR-2008, the patient was administered zoster vaccine live (ZOSTAVAX) by a healthcare provider in a pharmacy for the long-term prevention of shingles and zoster-related conditions (dose, route of administration, lot number and expiration date were not reported).  On an unknown date, the patient was treated by a healthcare provider the following injuries resulting from the patient's zoster vaccine live (ZOSTAVAX) use: shingles, Herpes Zoster ophthalmicus, varicella type rash, facial paralysis, right Bell's Palsy, and other zoster related injuries. The outcome of the events was not provided.  Upon internal review, the events Herpes zoster ophthalmicus, right Bell's Palsy, and facial paralysis were considered to be medically significant.
pt recvd vax; several hrs p/ dose 2, exp an itchy rash on her neck & face, alow grade t & achy joints;addtl,inject site was hot & tender;tx w/ dph; sxs subsided
This spontaneous report as received from a pharmacist refers to unknown number of patients of unknown age and gender. Patients concurrent conditions and relevant medical history was no reported. On an unknown dates (since 2 weeks), unknown number of patients were vaccinated with improperly stored ZOSTAVAX (lot number, dose and route unspecified). Concomitant medications were not reported. No adverse effects were reported. The outcome of the events was unknown. The causality of the events with ZOSTAVAX was not reported. Additional information has been requested.
Patient received vaccine at approximately 2 PM on 8/11/2015. Pt reported not feeling well starting at 8 PM that evening. Proceeded to throw up, feel feverish (no temp taken until 8/12/15 at 10:00 AM and at that time was 102 F). Felt weak, dizzy, and "delirious". Took Ibuprofen at midnight on 8/12/2-15 and Tylenol at 10:00 AM on 8/12/15. Mother called pt's PCP and spoke with a nurse about illness. Did not bring child in for treatment. Child recovered and was "much better" as of 8/13/15.
Contractured left arm with severe pain and complete loss of use for 24 hours, then 4 days before pain was completely gone and use of arm returned fully.
This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, or concomitant medications. On 25-JUN-2013, the patient was vaccinated with GARDASIL for prophylaxis (dose, route of administration, lot number and expiration date were not reported). Then, on 05-AUG-2016, the patient was vaccinated with GARDASIL 9 for prophylaxis (lot number reported as M011840, expiration date 01-FEB-2018; dose and route of administration were not reported) (interchange of vaccine products). No adverse effects were reported. The outcome of the event interchange of vaccine products and its causal relationship to therapy with GARDASIL and GARDASIL 9 were unknown. Additional information has been requested.
HEADACHE; A BRUISE AT THE SITE OF INJECTION THAT HAS THE SIZE OF A QUARTER; This spontaneous report received from a patient concerned a 51 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 18053, expiry: UNKNOWN) dose was not reported, administered on 01-APR-2021 to left deltoid for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced a bruise at the site of injection that has the size of a quarter. On 02-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from headache on 02-APR-2021, and had not recovered from a bruise at the site of injection that has the size of a quarter. This report was non-serious.
ON DAY OF VACCINATION DEVELOPED FEVER X 4 MORE DAYS WITH CHERRY RED SPOT AT SITE OF INJECTION. ATAXIC X 4 DAYS SCREAMING LIKE HE'S NEVER SCREAMED BEFORE. SEEN BY KP MD FELT HAD OM. PLACED ON OMNICEF DEVELOPED RASH 20 MINUTES PAST DOSE AND SEEN NEXT DAY AND OTITIS WAS GONE.
Approximately 3 hours after shot, patient started feeling dizzy & nauseated. Taken to ER, and admitted for dizziness, diarrhea, severe headache, chills, sweating, nausea & vomiting. Stayed in hospital for 2 days.
Patient has redness and swelling at injection site initially but it cleared up.  About 10 days after vaccine, the redness and swelling at injection site returned and the area continues to get bigger.  I advised patient to apply cold compress and benadryl cream, or take benadryl orally.  I will follow up with her in 2 days.
Continued fever, heaviness in my chest, breathlessness, sore throat, feeling really down
This case was reported by a healthcare professional and described the occurrence of could not walk in an adult female subject who was vaccinated with ENGERIX B (GlaxoSmithKline). Concurrent medical conditions included kiwi allergy and sinus infection. Concurrent medications included TUBERSOL. On 12 May 2009 at 16:30, the subject received 1st dose of ENGERIX B (unknown, left arm). On 13 May 2009, 1 day after vaccination with ENGERIX B, the subject experienced could not walk, loss of depth perception and increased blood pressure. On 14 May 2009, the events were resolved. The healthcare professional considered the events were unlikely to be related to vaccination with ENGERIX B. The subject received vaccine and the next day, she began to have the following symptoms: lack of depth perception so that she could not see where she should place her foot in order to walk, therefore she could not walk. Also subject experienced increased blood pressure of greater that 160 systolic. These symptoms resolved entirely the next day and since, subject was seen by primary care physician and ENT physician who stated that her reaction was probably not due to the ENGERIX vaccine but due to a sinus infection, she was suffering from. Follow-up information was received on 20 October 2009 from the reporting nurse. ENGERIX B was given in the left deltoid. ENGERIX B was not reintroduced. The nurse and subject discussed and the subject chose not to continue-risk versus benefit.
when she woke up this morning her left eye had a blood spot on the white part of the eye; soreness at the injection site; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 2 via an unspecified route of administration on 21Apr2021 (Batch/Lot number was not reported) as single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 on an unknown date for COVID-19 immunisation. On 23Apr2021, patient reported that when she woke up this morning her left eye had a blood spot on the white part of the eye and denied any injury or change in vision. The only other symptom reported was soreness at the injection site on an unknown date in Apr2021. The patient also reported that her husband and everyone I talk to has a sore arm after getting their injection. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pfizer-BioNTech COVID-19 Vaccine EUA: Two days after receiving vaccination patient presents to the emegency department for a near syncopal episode. Since vaccination patient reports fever (up to 101 degrees Fahrenheit), chills, light headedness, headache, and myalgias. In the emergency department vitals stable and within normal ranges including temperature 36.5 degrees Celsius. No rash, hives, or shortness of breath noted or reported. Patient adminsitered fluids with symptom improvement. Discharged to home stable.
pt complains of throat tightening sensation about 20-30 minutes post-covid vaccination Pfizer #1 today.  Has history of sulfamethoxazole/trimethoprim allergy, similar symptoms in the past w/ this, treated w/ benadryl only. Never has had anaphylaxis.    Vitals stable /slightly hypertensive today and 25 mgs IM diphenhydramine today.  Stable at discharge, symptoms have resolved,
5/7/2021: 2 am-4 am, 102F fever; chills; sweating; vomiting. 4 am - low temp 95F, intense malaise. 8 am-8 pm, diarrhea; severe vertigo; tinnitus; fainting. 5/8/2021-5/20/2021: Mobility issues from recent vertigo attack; several more vertigo attacks throughout the week; poor concentration; vomiting; tingling throughout body; fatigue; insomnia; enhanced anxiety. 5/20/2021-5/24/2021: Delayed cycle (extra 5 days and counting). All symptoms from 5/8 to 5/20 continue at half severity.
Anaphylaxis event; skin rash; redness; confusion; neck pain; throat pain; coughing; difficulty breathing; This is a spontaneous report from a contactable consumer (patient). A 32-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in Arm Left on 01May2021 12:00 (Lot Number: ewo158) as dose 2, single (at age of 32-years-old) for covid-19 immunisation. The patient medical history was not reported. If covid prior vaccination: Unknown. There were no concomitant medications. No other vaccine in four weeks. No other medications in two weeks. Historical Vaccine included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot No: ewo172) on 09Apr2021 12:00 PM Location of injection: Arm Left (at age of 32-years-old) for covid-19 immunisation. The patient previously took amoxycillin and experienced allergic to amoxycillin (was allergic to amoxycillin as a child, current tests show he was not allergic to the class). On 10May2021 10:30, the patient experienced anaphylaxis event, skin rash, redness, confusion, neck pain, throat pain, coughing, difficulty breathing. All events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event), disability or permanent damage. Therapeutic measures were taken for all events included benadryl, epinephrine, prednisone, intubation. The patient was hospitalized for 1 days. The event clinical course was as follows: initial anaphylaxis event occurred on 10May, second event occurred 12May, ongoing anaphylaxis symptoms have persisted for 3 months controlled only by Benadryl and prednisone. These symptoms included skin rash, redness, confusion, neck pain, throat pain and closure resulting in coughing and difficulty breathing. all other medications, foods, and sources have been eliminated over dozens of tests. symptoms are controlled well by cromolyn sodium, Pepcid, and compound Regimine. The patient underwent lab tests and procedures which included tests: not allergic to the class (was allergic to amoxycillin as a child, current tests show he was not allergic to the class) on an unspecified date, spike protein test: positive (blood test, Nasal Swab) on 01Sep2021. Outcome of the events was not recovered.
Cutaneous reaction 15x17 cm area with mild induration and increased warmth in the right deltoid; Increased warmth in the right deltoid; cutaneous reaction; This case was reported by a physician via call center representative and described the occurrence of induration in a 54-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 24th October 2019, the patient received Shingrix. On 25th October 2019, 1 days after receiving Shingrix, the patient experienced induration, localized feeling of warmth and skin reaction. On an unknown date, the outcome of the induration was not recovered/not resolved and the outcome of the localized feeling of warmth and skin reaction were unknown.   It was unknown if the reporter considered the induration, localized feeling of warmth and skin reaction to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The next day  of vaccination the patient developed a cutaneous reaction 15 by 17 cm area with mild induration and increased warmth in the right deltoid.   This event was ongoing at the time of this report. The HCP did not have the lot number or expiration date as the vaccine was not given at his office.
Sleep apnea; Influenza like illness; This spontaneous case was reported by a consumer and describes the occurrence of SLEEP APNOEA SYNDROME (Sleep apnea) and INFLUENZA LIKE ILLNESS (Influenza like illness) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Plaque psoriasis.    No Medical History information was reported.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced INFLUENZA LIKE ILLNESS (Influenza like illness). On an unknown date, the patient experienced SLEEP APNOEA SYNDROME (Sleep apnea). At the time of the report, SLEEP APNOEA SYNDROME (Sleep apnea) had not resolved and INFLUENZA LIKE ILLNESS (Influenza like illness) had resolved.            No concomitant products were reported.  On an unknown date, the patient experienced sleep apnea. In 2021, the patient experienced felt like flu after second vaccination. in 2021, the felt like flu after second vaccination resolved. Moderna covid-19 vaccine (elasomeran) was also considered suspect. It was unknown if patient was enrolled in a covid-19 vaccine trial. On 01-May-2021, patient received 1st dose covid-19 vaccine manufactured by moderna. On 30-May-2021, patient received 2nd dose covid-19 vaccine manufactured by moderna. Causality for humira (adalimumab) The reporter's causality for the event (s) of sleep apnea and felt like flu after second vaccination was not  provided.  No treatment information was reported by the reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.
After receiving Hep B soldier c/o not feeling well. Head starting "bobbing". Also noted tremors, c/o dizziness. Epi given x1 BP 120/64 63 02 98%. Soldier is alert and feels. Addendum-numbness noted in right arm refused to go to ER.
Received dose #1 of BEXSERO on 1/17/18. On the morning of 1/18/18 eyelids were swollen and itchy. Tops of both hands had pink spots and were painful and itchy. Given cetirizine 10mg and ranitidine 150mg po in clinic and advised to take as needed over the next 2-3 days.
This report was received from Pfizer (manufacturer report number: 2010107464). A female consumer reported that her niece, a currently four months old, race unknown, received ROTATEQ at an unknown dose for an unknown indication on an unknown date in 2010. Relevant medical history, concomitant medication and past drug history of the consumer were unknown. The reporter reported that her niece experienced "blood and blood clots in her stool on an unknown date in 2010, which started that night after receiving ROTATEQ" and the reporter also mentioned that the patient had ulcerative colitis and bleeding ulcers from an unknown date however, it was unknown whether these events happened before or after the vaccination. Relevant laboratory data of the patient was unknown however, the reporter mentioned that the patient would go for colonoscopy on 25-AUG-2010. Therapeutic measures taken in response to the event were unknown. At the time of report consumer had not recovered from the event blood and blood clots in her stool and the status of ROTATEQ was unknown. The reporter mentioned consumer had ulcerative colitis, bleeding ulcers and the reporter thought this could have caused the events. Blood and blood clots in her stool was considered to be an other important medical event by the reporter. This was originally reported by a consumer. Additional information has been requested.
The following morning had raised red swelling at injection site, approximately 2-inch diameter, very hot and tender. Burning abdominal pain (same type of pain as with allergic flare from progesterone), minor joint pains, fatigue, malaise. Took prescribed daily allergy meds as usual (zyrtec, montelukast, famotidine). The next morning, diameter had expanded to 3 inches, but redness, swelling, and tenderness had decreased. Other symptoms decreased, but PVCs from existing arrhythmia increased frequency/intensity. Continued prescribed allergy meds as usual. Day 3, no further expansion at injection site. All symptoms slowly improving.
Began with severe chills, a fever of 100F, body aches, hypersensitive skin, and a headache. After 24 hours, all symptoms subsided except for headache which continues. The headache feels very pressurized and is exacerbated greatly by bending down or standing from sitting/laying position. Pet my doctor's instructions, I'm currently dosing with Tylenol, resting, and drinking plenty of water. There has not yet been an improvement in the headache